Management & Regulatory

Quantum BioPharma Sues CIBC and RBC for Alleged Spoofing and Losses
Management & Regulatory Quantum BioPharma Sues CIBC and RBC for Alleged Spoofing and Losses

Quantum BioPharma Ltd., a biotech firm specializing in neurodegenerative and metabolic disorders, has recently taken legal action against CIBC World Markets and RBC Dominion Securities. The lawsuit, filed in the United States District Court for the Southern District of New York, claims that these

CVS Health Replaces CEO Amid Financial Strain and Strategic Shifts
Management & Regulatory CVS Health Replaces CEO Amid Financial Strain and Strategic Shifts

In a surprising move to address ongoing financial difficulties and strategic challenges, CVS Health has made a significant leadership change by replacing CEO Karen Lynch with David Joyner, head of Caremark. This transition underscores the pressing need for CVS to stabilize its operations and refine

Are Biopharma Companies Ready for Today's Regulatory Challenges?
Management & Regulatory Are Biopharma Companies Ready for Today's Regulatory Challenges?

Are Biopharma Companies Ready for Today's Regulatory Challenges? The biopharmaceutical sector is rapidly evolving, with companies constantly innovating to develop new treatments for a variety of diseases. However, navigating the regulatory landscape remains a significant challenge. Stricter

Pharma M&A Trends: High-Value Focus and Innovation Amid Market Fluctuations
Management & Regulatory Pharma M&A Trends: High-Value Focus and Innovation Amid Market Fluctuations

In recent years, the pharmaceutical and biotechnology sectors have experienced a dynamic landscape in mergers and acquisitions (M&A). From major multimillion-dollar deals to strategic acquisitions targeting high-demand therapeutic areas, the industry has witnessed fluctuations driven by various

Sutro Biopharma's Revenue Growth Fails to Boost Long-Term Stock Value
Management & Regulatory Sutro Biopharma's Revenue Growth Fails to Boost Long-Term Stock Value

Sutro Biopharma, Inc. (NASDAQ:STRO) has experienced a dramatic drop in its stock value over the last three years, significantly impacting its shareholders who have seen their investments diminish by 80%. Despite the company's impressive annual revenue growth of 38%, this financial success

Why Did the FDA Halt Novavax's COVID-Flu Vaccine Trials?
Management & Regulatory Why Did the FDA Halt Novavax's COVID-Flu Vaccine Trials?

The U.S. Food and Drug Administration (FDA) recently paused clinical trials for Novavax's combination COVID-19 and influenza vaccine, as well as its standalone flu vaccine. This unexpected halt was prompted by a serious adverse event involving motor neuropathy in a participant from the Phase 2

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later